FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147811178> ?p ?o ?g. }

• W2147811178 endingPage "2348" @default.
• W2147811178 startingPage "2332" @default.
• W2147811178 abstract "Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) tyrosine kinases. In March 2007, the US Food and Drug Administration approved lapatinib for use in combination with capecitabine in the treatment of advanced breast cancer overexpressing HER2 (HER2+).The goals of this review were to summarize the pharmacology, pharmacokinetics, efficacy, and tolerability of lapatinib, and to review studies of the approved and investigational uses of lapatinib.English-language reports of clinical trials of lapatinib in patients with cancer were identified through searches of PubMed/MEDLINE (1990-October 2009) and the American Society of Clinical Oncology abstracts database (2003-2008). Search terms included lapatinib, Tykerb, HER2, EGFR, breast cancer, dual tyrosine kinase inhibitor, and GW572016.Lapatinib was well tolerated in a Phase II monotherapy trial in patients with advanced breast cancer; however, the response was minimal in HER2+ patients, and no HER2- patients achieved an objective tumor response. A Phase II trial of lapatinib monotherapy in 39 HER2+ patients with breast cancer and brain metastases yielded 1 partial response, although 15.4% of patients had stable disease for > or =16 weeks. In a Phase III trial comparing lapatinib plus capecitabine with capecitabine alone in HER2+ patients with advanced breast cancer that had progressed after trastuzumab therapy, the median time to progression was 8.4 months with combination therapy, compared with 4.4 months with capecitabine alone (P < 0.001). There were no significant differences between combination therapy and capecitabine alone in terms of the overall response rate (22% and 14%, respectively) or overall survival.Lapatinib monotherapy was well tolerated, although the response rate was low in patients with advanced breast cancer. Lapatinib combined with capecitabine was associated with significant improvements in the time to progression and response rate compared with capecitabine alone. The available evidence suggests that clinical efficacy in breast cancer is limited to HER2+ disease." @default.
• W2147811178 created "2016-06-24" @default.
• W2147811178 creator A5016348831 @default.
• W2147811178 creator A5084695166 @default.
• W2147811178 date "2009-01-01" @default.
• W2147811178 modified "2023-09-30" @default.
• W2147811178 title "Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer" @default.
• W2147811178 cites W1901376003 @default.
• W2147811178 cites W1964321121 @default.
• W2147811178 cites W1965734230 @default.
• W2147811178 cites W1967763477 @default.
• W2147811178 cites W1973555911 @default.
• W2147811178 cites W1982729445 @default.
• W2147811178 cites W1992137963 @default.
• W2147811178 cites W2000798782 @default.
• W2147811178 cites W2004114072 @default.
• W2147811178 cites W2012784647 @default.
• W2147811178 cites W2013492426 @default.
• W2147811178 cites W2016323110 @default.
• W2147811178 cites W2033779255 @default.
• W2147811178 cites W2035156119 @default.
• W2147811178 cites W2040142253 @default.
• W2147811178 cites W2045950562 @default.
• W2147811178 cites W2064047613 @default.
• W2147811178 cites W2066893161 @default.
• W2147811178 cites W2073747667 @default.
• W2147811178 cites W2076708539 @default.
• W2147811178 cites W2087023176 @default.
• W2147811178 cites W2087823432 @default.
• W2147811178 cites W2095156669 @default.
• W2147811178 cites W2096074600 @default.
• W2147811178 cites W2096849721 @default.
• W2147811178 cites W2098523473 @default.
• W2147811178 cites W2109402423 @default.
• W2147811178 cites W2110444464 @default.
• W2147811178 cites W2112720107 @default.
• W2147811178 cites W2119997685 @default.
• W2147811178 cites W2123206362 @default.
• W2147811178 cites W2125956833 @default.
• W2147811178 cites W2128307445 @default.
• W2147811178 cites W2128804411 @default.
• W2147811178 cites W2129488628 @default.
• W2147811178 cites W2133051701 @default.
• W2147811178 cites W2136704455 @default.
• W2147811178 cites W2140684853 @default.
• W2147811178 cites W2141393790 @default.
• W2147811178 cites W2142752401 @default.
• W2147811178 cites W2146406055 @default.
• W2147811178 cites W2151193856 @default.
• W2147811178 cites W2152647863 @default.
• W2147811178 cites W2153457729 @default.
• W2147811178 cites W2157345824 @default.
• W2147811178 cites W2158158704 @default.
• W2147811178 cites W2161097683 @default.
• W2147811178 cites W2161574596 @default.
• W2147811178 cites W2164190676 @default.
• W2147811178 cites W2168814163 @default.
• W2147811178 cites W2600052071 @default.
• W2147811178 cites W2600981608 @default.
• W2147811178 cites W4234528300 @default.
• W2147811178 cites W4234578822 @default.
• W2147811178 doi "https://doi.org/10.1016/j.clinthera.2009.11.029" @default.
• W2147811178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20110044" @default.
• W2147811178 hasPublicationYear "2009" @default.
• W2147811178 type Work @default.
• W2147811178 sameAs 2147811178 @default.
• W2147811178 citedByCount "97" @default.
• W2147811178 countsByYear W21478111782012 @default.
• W2147811178 countsByYear W21478111782013 @default.
• W2147811178 countsByYear W21478111782014 @default.
• W2147811178 countsByYear W21478111782015 @default.
• W2147811178 countsByYear W21478111782016 @default.
• W2147811178 countsByYear W21478111782017 @default.
• W2147811178 countsByYear W21478111782018 @default.
• W2147811178 countsByYear W21478111782019 @default.
• W2147811178 countsByYear W21478111782020 @default.
• W2147811178 countsByYear W21478111782021 @default.
• W2147811178 countsByYear W21478111782022 @default.
• W2147811178 countsByYear W21478111782023 @default.
• W2147811178 crossrefType "journal-article" @default.
• W2147811178 hasAuthorship W2147811178A5016348831 @default.
• W2147811178 hasAuthorship W2147811178A5084695166 @default.
• W2147811178 hasConcept C121608353 @default.
• W2147811178 hasConcept C126322002 @default.
• W2147811178 hasConcept C143998085 @default.
• W2147811178 hasConcept C197934379 @default.
• W2147811178 hasConcept C2775930923 @default.
• W2147811178 hasConcept C2777329042 @default.
• W2147811178 hasConcept C2777909004 @default.
• W2147811178 hasConcept C2778375690 @default.
• W2147811178 hasConcept C2778820342 @default.
• W2147811178 hasConcept C2779438470 @default.
• W2147811178 hasConcept C2779786085 @default.
• W2147811178 hasConcept C526805850 @default.
• W2147811178 hasConcept C530470458 @default.
• W2147811178 hasConcept C71924100 @default.
• W2147811178 hasConcept C98274493 @default.
• W2147811178 hasConceptScore W2147811178C121608353 @default.

• next